Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468965 | 0.94 | SRD5A2 (0.62) | HSD11B1POLBHTR2AHTR2CHTR7 | |
| SCHEMBL31164032 | 0.91 | HSD11B1 (0.68) | HSD11B1POLBHTR2AHTR2CHTR7 | |
| SCHEMBL662115 | 0.91 | HSD11B1 (0.68) | HSD11B1POLBHTR2AHTR2CHTR7 | |
| Bicarbonate SCHEMBL11466272 | 0.88 | HSD11B1 (0.64) | HSD11B1POLBHTR2AHTR2CHTR7 | |
| SCHEMBL8110383 | 0.84 | MEN1 (0.59) | HSD11B1POLBHTR2AHTR2CHTR7 | |
| Bromide SCHEMBL9092341 | 0.83 | MEN1 (0.58) | HSD11B1POLBHTR2AHTR2CHTR7 | |
| SCHEMBL4671500 | 0.82 | HSD11B1 (0.58) | HSD11B1POLBHTR2AHTR2CHTR7 | |
| SCHEMBL22519116 | 0.82 | HSD11B1 (0.59) | HSD11B1POLBHTR2AHTR2CHTR7 | |
| SCHEMBL28551476 | 0.82 | HSD11B1 (0.58) | HSD11B1POLBHTR2AHTR2CHTR7 | |
| SCHEMBL228259 | 0.82 | MEN1 (0.67) | HSD11B1POLBHTR2AHTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11667606-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667606-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667606-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3814347-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210053917-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053917-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| CN-1809553-A | Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
| EP-1615909-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| EP-0823423-B1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-6586456-B1 | Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide | SANOFI-SYNTHELABO (FR) | 2003-07-01 | — | — | US | disclosed |
| CN-1188471-A | 1,4-disubstituted piepridine derivatives | BANYU PHARMA CO LTD (JP) | 1998-07-22 | — | — | CN | disclosed |
| US-5750540-A | SIDE EFFECT REDUCTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0823423-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| US-4043790-A | 2-OR 4-SUBSTITUTED PYRIDINE METHANE OR PYRIDINE METHANOL, NONHERBICIDAL | ELI LILLY AND COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667606-B2 | Thyromimetics | TPO, TSHR, TTR | HSD11B1 114/4885POLB 3668/4885HTR2A 705/4885 |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | HSD11B1 2990/4885POLB 2331/4885HTR2A 28/4885 |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | HSD11B1 1240/4885POLB 579/4885HTR2A 4792/4885 |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | HSD11B1 1240/4885POLB 579/4885HTR2A 4792/4885 |
| US-20210053917-A1 | NOVEL THYROMIMETICS | TPO, TSHR, CHRM1 | HSD11B1 72/4885POLB 3716/4885HTR2A 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.